Meeting
2022 ASCO Annual Meeting
Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC.
Authors
Kirby P Gardner
Creatv MicroTech, Inc., Monmouth Junction, NJ
Kirby P Gardner , Daniel L Adams , Pablo Lopez Bravo , Jianzhong He , Yawei Qiao , Ting Xu , Zhongxing X. Liao , Cha-Mei Tang , Steven H. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3054)
DOI
10.1200/JCO.2022.40.16_suppl.3054
Abstract #
3054
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.
First Author: Steven H. Lin
Poster
2021 ASCO Annual Meeting
Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.
First Author: Alex K. Bryant
Poster
2024 ASCO Breakthrough
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
First Author: Vincent T. Ma
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse